Evidence map›Paper›PMID 36721637›Full record

ArticleJournal of hepatocellular carcinoma2023

Changes in Presentation, Treatment, and Survival of Patients with Hepatocellular Carcinoma in Damietta, Egypt, 2007-2019: A Retrospective Monocentric Cohort Study.

Kévin Jean, Ahmed Tawheed, Liem Binh Luong Nguyen, Tarek Heikal, Usama Eldaly, Neveen Elhadidy, Ahmed Elghaieb, Ahmed Aboudonia, Laura Tondeur, Amélie Dublineau and 2 more

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kévin JeanLaboratoire MESuRS, Conservatoire national des arts et métiers, Paris, France.ORCID 0000-0001-6462-7185
Ahmed TawheedEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.ORCID 0000-0002-9382-8733
Liem Binh Luong NguyenEmerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France.
Tarek HeikalMedical Oncology Department, Damietta Oncology Center, Damietta, Egypt.
Usama EldalyMedical Oncology Department, Damietta Oncology Center, Damietta, Egypt.
Neveen ElhadidyPharmaceutical Services Department, Damietta Oncology Center, Damietta, Egypt.
Ahmed ElghaiebRadiology Department, Damietta Oncology Center, Damietta, Egypt.ORCID 0000-0002-1963-3858
Ahmed AboudoniaRadiology Department, Damietta Oncology Center, Damietta, Egypt.
Laura TondeurLaboratoire MESuRS, Conservatoire national des arts et métiers, Paris, France.
Amélie DublineauEmerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France.
Arnaud FontanetUnité PACRI, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France.
Mohamed El-KassasEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.ORCID 0000-0002-3396-6894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: We aimed to assess temporal changes in the presentation and survival of patients with hepatocellular carcinoma (HCC) in the northern Egypt region, one of the regions reporting the highest incidence of the disease globally. Methods: We conducted a monocentric retrospective study. Patients presenting at the Damietta Oncology referral center between 2007 and 2019 with a diagnosed HCC were eligible. Individual, clinical and tumor characteristics at HCC diagnosis, including the Barcelona Clinic Liver Cancer (BCLC) staging, were retrieved from medical files and patients' final vital status was ascertained by combining various data sources. Patients were divided into 2 groups based on diagnosis period: pre- and post-2014. Survival was analysed based on Kaplan-Meier curves and differences in restricted mean survival time (RMST). Results: Data from 5097 patients (among 5210 eligible, 97.8%) were analyzed. We observed a significant trend toward HCC diagnosed at earlier stage in the post- vs pre-2014 period (BCLC stage 0/A or B: 37.2% vs 27.1%, p<10 Discussion: Overall survival after HCC diagnosis in Egypt remains poor but is significantly improved by curative therapy. Despite a trend toward earlier diagnosis of HCC, we did not observe a general improvement in survival over time, which remains to be clearly understood.

Indexed as

Egyptepidemiologyhepatocellular carcinomaliver cancerstaging systemsurvival

Identifiers

PMID36721637
PMCPMC9884455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.